The good news is, based on clinical trials in South Africa, the Johnson & Johnson vaccine is considered effective in preventing the severity and mortality of Beta and Delta variants of Corona virus. Even in just one injection dose without a booster.
This study is the world’s first real test of the vaccine’s effectiveness against Delta, a highly contagious viral variant that is rapidly spreading around the world. The South African Ministry of Health reported these preliminary results at a press conference on Friday (6/7/2021). However, the data have not been reviewed or published in scientific journals.
In a trial called Sisonke, researchers evaluated a single dose of Johnson & Johnson vaccine on nearly 500,000 health care workers, who are at high risk for COVID-19. The vaccine has an efficacy of up to 95 percent against deaths from Delta variants, and up to 71 percent against inpatients, the researchers said.
"We believe this vaccine does what it was designed to do, which is to stop people from going to the hospital and stop them ending up in the ICU and dying," Drs. Linda-Gail Bekker, head of research and director of the Desmond Tutu HIV Center at the University of Cape Town, as reported by The New York Times.
"The results show that people who have received a single dose of Johnson & Johnson vaccine do not need booster encouragement."
The researchers found that in volunteers who were vaccinated, cases of mild symptoms were 96 percent, while those resulting in severe illness or death were less than 0.05 percent.
The test results are certainly good news for the millions of people who have received the Johnson & Johnson vaccine. Since several previous studies have shown that one injection may be prone to Delta, it is recommended to perform another promotion.
As a result, some Johnson & Johnson vaccine recipients have obtained their own second doses. Health officials in San Francisco are even offering the Pfizer-BioNTech or Moderna vaccine to residents who are immunized with additional doses of Johnson & Johnson.
"This study was conducted as a real -world efficacy study in one of the most challenging epidemiological environments," said Drs. And Barouch, a virologist at Beth Israel Deaconess Medical Center in Boston who has led several studies for J.&J. "This is good news for combating the global COVID-19 epidemic."
South Africa itself approved the Johnson & Johnson vaccine in April.The country has faced a surge of Delta variants in recent weeks.
More than 8 million South Africans have received the Johnson & Johnson vaccine or at least one dose of Pfizer vaccine.
Tags
NEWS & FACT
